News Related to Melanocortin 4 Receptor

Related coverage linked through entity extraction aliases.

Three Drugmakers Advance Obesity Pipelines with New Mechanisms and Clinical Plans

Mar 01, 2026

Amgen, Celltrion, and Palatin Technologies are advancing obesity drug candidates through clinical development, with trials planned for 2026-2028 targeting liver fat reduction, multiple biological pathways, and rare genetic obesity conditions.

FDA Decisions Expected in March 2026 for Multiple Biotech Drug Candidates

Feb 16, 2026

The FDA is set to announce decisions in March 2026 on several drug applications, including label expansions for approved therapies and new drug candidates, with some making repeat approval attempts.